NOTVQ · Inotiv, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result, substantial doubt about the Company's ability to continue as a going concern exists.”View the 10-Q filed May 11, 2026
Price & Indicators
The closing range uses available history since Jul 17, 2026; less than a full year is stored.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NOTVQ
this stock
Inotiv, Inc.
|
$387,258 | — | +511.2% | — | 5.5% |
|
TMO
Thermo Fisher Scientific Inc.
|
$249.58B | +13.0% | +14.5% | 36.3 | 1.4% |
|
DHR
Danaher Corp /De/
|
$150.37B | -6.5% | +8.5% | 37.9 | 1.2% |
|
NTRA
Natera, Inc.
|
$59.47B | +79.1% | -2.8% | — | 3.3% |
|
A
Agilent Technologies, Inc.
|
$48.90B | +23.3% | +6.4% | 34.2 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NOTVQ | — | — | — | — | — |
| SPY | -1.5% | +0.3% | +7.8% | -0.5% | +9.0% |
| vs SPY | — | — | — | — | — |